NOVO-NORDISK A/S-SPONS ADR (NVO)

Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?

Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.

Interesting NVO Put And Call Options For January 2025

Is Novo Nordisk Stock a Buy Right Now?

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

3 Growth Stocks You Can Buy Right Now Without Any Hesitation

Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.

Mergers and acquisitions could make a comeback with Trump headed back to Washington.

Novo-Nordisk Becomes Oversold (NVO)

While growth is established for NYSE:NVO, the stock's valuation remains reasonable.

Investors should take note ofNOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced.

See Which Of The Latest 13F Filers Holds Novo-Nordisk

Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot

Shares were rattled Tuesday after a report showed its obesity treatment can cause lower bone mineral density.

Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot

The company is testing MariTide as a monthly shot, rivaling weekly injections from Novo Nordisk and Eli Lilly.

Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?

The good times aren't over, but the peak of the party might be passing.

Is Viking Therapeutics a Buy on the Dip?

Viking stock has slipped more than 20% from its peak.

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review

A Fed rate cut and a slew of big earnings reports filled out a busy week.

Investors Like Certainty. Trump's Win Gave Them Some.

We're also talking about Super Micro, Nvidia, and weight loss.

Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript

NVO earnings call for the period ending September 30, 2024.

Novo Nordisk Dips After Tightening Its Outlook As Wegovy Beats, But Ozempic Misses

The company also tightened its sales outlook for the year.